
Bladder Cancer Therapeutics And Diagnostics Market
Bladder Cancer Therapeutics and Diagnostics Market Forecasts to 2030 - Global Analysis by Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer and Other Cancer Types), Therapeutics, Diagnostics, Treatment Stage, End User and By Geography

Years Covered |
2022-2030 |
Estimated Year Value (2024) |
US $471.5 MN |
Projected Year Value (2030) |
US $786.4 MN |
CAGR (2024 - 2030) |
8.9% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Bladder Cancer Therapeutics and Diagnostics Market is accounted for $471.5 million in 2024 and is expected to reach $786.4 million by 2030 growing at a CAGR of 8.9% during the forecast period. Bladder cancer therapies and diagnostics are the medical treatments and technologies used to manage and identify bladder cancer. Therapeutics includes a range of treatments such as surgery, chemotherapy, immunotherapy, radiation therapy, and targeted therapy, aimed at killing cancer cells or preventing their growth. Diagnostics involve various tests and procedures, such as urine tests, cystoscopy, imaging (e.g., CT scans, ultrasounds), and biopsy, to detect and stage the cancer. Early detection and advanced treatments are crucial for improving survival rates, and ongoing research in personalized medicine is enhancing the effectiveness of both therapeutic and diagnostic approaches.
According to the American Cancer Society, in 2022, there are around 81,180 new cases of bladder cancer 61,700 in men and 19,480 in women in the United States.
Market Dynamics:
Driver:
Rising Incidence of Bladder Cancer
The rising incidence of bladder cancer is extensively driving the bladder cancer therapeutics and diagnostics market. As more individuals are diagnosed, there is increased demand for advanced diagnostic tools, such as imaging and biomarker testing, and innovative treatment options, including targeted therapies, immunotherapies, and chemotherapy. This growing need for early detection and personalized treatments is propelling market growth, with healthcare providers and pharmaceutical companies focusing on developing novel therapies and diagnostic solutions to address the rising prevalence of bladder cancer.
Restraint:
High Treatment Costs
The high expense of bladder cancer diagnostics and treatments is a significant barrier to market expansion, especially in low- and middle-income nations. Patient access and affordability are restricted by the high cost of modern medicines, such as immunotherapies and targeted treatments. This problem is made worse by gaps in insurance coverage and out-of-pocket costs, which obstruct prompt diagnosis and efficient treatment, delaying patient results and impeding wider market adoption.
Opportunity:
Early Detection Technologies
Early detection technologies are significantly impacting the bladder cancer therapeutics and diagnostics market by enabling earlier diagnosis, improving treatment outcomes, and reducing mortality rates. Technologies such as liquid biopsy, imaging advancements, and biomarker testing allow for the identification of cancer at its initial stages, leading to personalized treatment plans. This enhances the efficiency of therapies, minimizes side effects, and reduces healthcare costs. As a result, the market for bladder cancer diagnostics and treatments is expanding rapidly, driven by these innovations.
Threat:
Side Effects of Treatments
The adverse effects of bladder cancer therapies such as chemotherapy, immunotherapy, and radiation impede market growth by decreasing patient adherence and treatment efficacy. Fatigue, nausea, and immune-related problems are examples of adverse effects that might lower quality of life and cause therapy to be stopped or postponed. Patients and healthcare professionals become concerned about this, which slows the uptake of some treatments and hinders the market's overall growth for bladder cancer treatments and diagnostics.
Covid-19 Impact:
The COVID-19 pandemic disrupted the Bladder Cancer Therapeutics and Diagnostics Market by delaying elective surgeries, reducing patient visits, and limiting clinical trials. Diagnostic testing and treatment availability were impacted, leading to treatment postponements. However, the growing focus on cancer care post-pandemic, along with accelerated adoption of telemedicine and remote diagnostics has supported market recovery, driving demand for innovative therapies and diagnostic solutions in the long term.
The cystoscopy segment is expected to be the largest during the forecast period
The cystoscopy segment is expected to be the largest during the forecast period as it allows for direct visualization of the bladder lining, aiding in the identification of tumors or abnormalities. This diagnostic tool supports biopsy procedures, contributing to more precise treatment planning. As bladder cancer cases increase globally, cystoscopy's role in early-stage diagnosis and subsequent therapeutic interventions is driving growth in both the diagnostics and therapeutics sectors.
The radiotherapy segment is expected to have the highest CAGR during the forecast period
The radiotherapy segment is expected to have the highest CAGR during the forecast period because it is often combined with surgery or chemotherapy to improve survival rates. Advances in radiotherapy techniques, such as image-guided radiation therapy (IGRT) and intensity-modulated radiation therapy (IMRT), have enhanced precision, reducing side effects. These innovations are driving the market, along with the increasing demand for advanced diagnostic tools to monitor treatment efficacy and detect recurrence.
Region with largest share:
North America is anticipated to hold the largest market share during the forecast period because of the rising prevalence of bladder cancer, improvements in diagnostic tools, and the expanding need for focused treatments. The aging of the population and the increase in smoking are important variables that lead to increased cancer rates. Furthermore, advances in non-invasive diagnostic technologies and immunotherapies, as well as increased healthcare access and research funding, are driving market expansion in the area.
Region with highest CAGR:
Asia Pacific is anticipated to witness the highest CAGR over the forecast period owing to rising cancer incidences, increasing healthcare awareness, advancements in diagnostic technologies, and growing demand for targeted therapies. The region’s expanding healthcare infrastructure and the adoption of minimally invasive procedures also contribute to market growth. Additionally, ongoing research into novel biomarkers and immunotherapies, along with enhanced access to advanced treatments, are boosting the adoption of innovative diagnostic and therapeutic solutions for bladder cancer in Asia-Pacific.
Key players in the market
Some of the key players in Bladder Cancer Therapeutics and Diagnostics market include Abbott Laboratories, AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Endo Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., GlaxoSmithKline PLC, Hoffmann-La Roche AG, Johnson & Johnson, Kaiser Permanente, Merck & Co., Inc., Novartis International AG, Pacific Edge Limited, Pfizer Inc. and Sanofi S.A.
Key Developments:
In September 2024, iCardio.ai announced collaboration with Abbott to develop AI applications for the medtech giant’s imaging technologies.
In August 2024, Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading1 FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.
In August 2024, The American Diabetes Association and Abbott recently announced a collaboration to better understand the nutritional needs of people living with diabetes, obesity, and metabolic dysfunction and how nutrition formulas can support those needs and overall health.
Cancer Types Covered:
• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types
Therapeutics Covered:
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiotherapy
• Surgical Procedures
• Other Therapeutics
Diagnostics Covered:
• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Biopsy
• Blood Tests
• Other Diagnostics
Treatment Stages Covered:
• Early-Stage Bladder Cancer
• Advanced-Stage Bladder Cancer
End Users Covered:
• Hospitals
• Cancer Research Institutes
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type
5.1 Introduction
5.2 Transitional Cell Bladder Cancer
5.3 Squamous Cell Bladder Cancer
5.4 Other Cancer Types
6 Global Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics
6.1 Introduction
6.2 Chemotherapy
6.3 Immunotherapy
6.4 Targeted Therapy
6.5 Radiotherapy
6.6 Surgical Procedures
6.7 Other Therapeutics
7 Global Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics
7.1 Introduction
7.2 Cystoscopy
7.3 Bladder Ultrasound
7.4 Urinalysis
7.5 Biopsy
7.6 Blood Tests
7.7 Other Diagnostics
8 Global Bladder Cancer Therapeutics and Diagnostics Market, By Treatment Stage
8.1 Introduction
8.2 Early-Stage Bladder Cancer
8.3 Advanced-Stage Bladder Cancer
9 Global Bladder Cancer Therapeutics and Diagnostics Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Cancer Research Institutes
9.4 Diagnostic Laboratories
9.5 Ambulatory Surgical Centers
9.6 Other End Users
10 Global Bladder Cancer Therapeutics and Diagnostics Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Abbott Laboratories
12.2 AstraZeneca PLC
12.3 Bristol-Myers Squibb Company
12.4 Celgene Corporation
12.5 Eli Lilly and Company
12.6 Endo Pharmaceuticals Inc.
12.7 F. Hoffmann-La Roche Ltd
12.8 Genentech, Inc.
12.9 GlaxoSmithKline PLC
12.10 Hoffmann-La Roche AG
12.11 Johnson & Johnson
12.12 Kaiser Permanente
12.13 Merck & Co., Inc.
12.14 Novartis International AG
12.15 Pacific Edge Limited
12.16 Pfizer Inc.
12.17 Sanofi S.A.
List of Tables
1 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Region (2022-2030) ($MN)
2 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Type (2022-2030) ($MN)
3 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Transitional Cell Bladder Cancer (2022-2030) ($MN)
4 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Squamous Cell Bladder Cancer (2022-2030) ($MN)
5 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Cancer Types (2022-2030) ($MN)
6 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Therapeutics (2022-2030) ($MN)
7 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Chemotherapy (2022-2030) ($MN)
8 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Immunotherapy (2022-2030) ($MN)
9 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Targeted Therapy (2022-2030) ($MN)
10 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Radiotherapy (2022-2030) ($MN)
11 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Surgical Procedures (2022-2030) ($MN)
12 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Therapeutics (2022-2030) ($MN)
13 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostics (2022-2030) ($MN)
14 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cystoscopy (2022-2030) ($MN)
15 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Bladder Ultrasound (2022-2030) ($MN)
16 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Urinalysis (2022-2030) ($MN)
17 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Biopsy (2022-2030) ($MN)
18 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Blood Tests (2022-2030) ($MN)
19 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other Diagnostics (2022-2030) ($MN)
20 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Treatment Stage (2022-2030) ($MN)
21 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Early-Stage Bladder Cancer (2022-2030) ($MN)
22 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Advanced-Stage Bladder Cancer (2022-2030) ($MN)
23 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By End User (2022-2030) ($MN)
24 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)
25 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
26 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
27 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
28 Global Bladder Cancer Therapeutics and Diagnostics Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?

Assured Quality
Best in class reports with high standard of research integrity

24X7 Research Support
Continuous support to ensure the best customer experience.

Free Customization
Adding more values to your product of interest.

Safe & Secure Access
Providing a secured environment for all online transactions.

Trusted by 600+ Brands
Serving the most reputed brands across the world.